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The differential diagnosis of nonpituitary sellar masses 
in children is broad. It includes germ cell tumors, gliomas, 
meningiomas, metastatic tumors, vascular lesions, and 
granulomatous, infectious, and inflammatory processes in 
the intrasellar area. Furthermore, the physiologic increase 
in the size of pituitary gland during puberty may be 
observed causing confusion with pituitary adenoma. 
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Although boys may have enlargement of pituitary glands, 
typically, these are less than 7 to 8 mm[1]. Even though 
it rarely happened, primary hypothyroidism may be 
complicated by an enlarged pituitary gland, particularly in 
children. Earlier studies showed long-standing untreated 
hypothyroidism may result in enlargement of pituitary 
glands. The subsequent regression of glands with thyroxine 
therapy indicated pituitary hyperplasia rather than adenoma 
or other cause of sellar masses. This should be clinically 
apparent and resolved within a few months of 
treatment[2,3]. However, neurosurgery for a presumed 
primary pituitary tumor has been unnecessarily performed 
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ABSTRACT
Pituitary hyperplasia associated with untreated primary hypothyroidism in children is a rare condition. There 
are only a few reports on this condition in children, and especially when pituitary hyperplasia is accompanied 
with Hashimoto thyroiditis and growth arrest. Here, we describe an unusual association of pituitary hyperplasia 
with hypothyroidism and growth retardation, and this was all caused by Hashimoto thyroiditis. Hormonal 
testing showed a low thyroxine level and a high thyroid stimulating hormone level, elevated anti-thyroglobulin, 
low growth hormone levels and prepubertal levels of gonadotropins. A large intrasellar mass expanding beyond 
the sella turcica was detected on magnetic resonance imaging (MRI). Homogeneous contrast enhancement of 
mass highly suggested that it was a pituitary hyperplasia rather than a pituitary tumor. Therapy with 
L-thyroxine resulted in rapid improvement of the clinical signs, including renewed growth, normalization of 
the hormone levels and resolution of the pituitary hyperplasia on MRI within 90 days. In children, prolonged 
unrecognized primary hypothyroidism might be accompanied by growth deficiency and pubertal disharmony. 
Physicians must be aware of pituitary hyperplasia in these cases. (J Korean Endocr Soc 25:72~77, 2010)
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in cases of secondary pituitary enlargement in adults[4] 
and also in children as recently reported[5].
Our observation emphasizes the importance of diagnosing 
and treating primary hypothyroidism prior to considering 
surgery for confirmation of possible pituitary adenoma, 
especially in children. A brief review of related literatures 
was also made.
Case Report
A 15-year-old boy presented to his local hospital with 
complaints of short stature, weight gain and chronic 
fatigue. He was diagnosed with hypothyroidism when he 
was found to have a thyroid stimulating hormone (TSH) 
of 50 mIU/mL, and free T4 of 0.64 pmol/L, 1 month 
before. As the finding by brain computed tomography 
(CT) was suggestive of a pituitary tumor, he was referred 
for further neurosurgical evaluation. Sellar magnetic 
resonance imaging (MRI) revealed a greatly enlarged pit
uitary gland with homogeneous pituitary tissue (Fig. 1). 
Elbow, knee and pelvis X-ray revealed that the bone age 
of the patient was 11 years classified based on the 
Greulich-Pyle system. The appearance was thought to be 
consistent with a pituitary macroadenoma and the patient 
was referred for an endocrinology opinion. 
Ophthalmological examinations, including visual fields 
test, were performed showing grossly intact and no 
proptosis. His thyroid gland was palpable and soft without 
any nodules. His chest X-ray was clear, and cardiac 
examination revealed a regular rhythm without murmurs. 
Neurologically, his reflexes were not delayed, and there 
was no tremor. His skin was cool and dry. He was 
prepubertal. His height was on the less than 3rd centile 
and weight on the 50th centile. Results of serial 
endocrinological parameters are shown in Table 1. He was 
diagnosed with normocytic anemia (hemoglobin 103 g/L), 
and hypercholesterolemia (8.42 mmol/L). Combined 
pituitary function test was also performed (Table 2). His 
TSH level was higher than 50 mIU/mL and free T4 was 
extremely low, at 0.05 ng/dL. Random growth hormone 
(GH) was less than 0.01 and insulin-like growth 
factor(IGF)-1 level was 12.66 nmol/L (normal 
26.46~126.67). Goiter was noted and his anti-thyroid 
peroxidase (TPO) antibody level was elevated (> 3,000 
U/mL, normal < 60 U/mL). Ultrasound scanning of the 
thyroid revealed a normally placed gland with increased 
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Fig. 1. Brain magnetic resonance imaging (MRI) before treatment and after treatment. Interval change of brain MRI at 
presentation (A, B) and after 3 months of thyroxine treatment (C, D) (Enlarged pituitary glands with homogeneous pituitary tissue 
mimicking a pituitary macroadenoma).
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vascularity. Diagnoses of severe Hashimoto’s thyroiditis 
with secondary pituitary hyperplasia and growth hormone 
deficiency were finally made. The patient began oral 
levothyroxine (100 μg a day) and growth hormone 
replacement (3 mg, every each 5 days, Somatropin 
subcutaneous injection). The patient became clinically and 
biochemically euthyroid and his IGF-1 level was in 
normal range (46.78 nmol/L) (Table 1). Repeated MRI a
fter 3 months of treatment showed dramatic reduction in 
the size of the pituitary gland to almost normal size (Fig. 
1). His height initially increased to the level of 10th 
centile, then continued to increase along the 50th centile. 
In addition, he had signs of early pubertal development.
 
Discussion
The chief complaint of the patient in this case was 
growth retardation. The discrepancy between bone age and 
chronologic age was 28 months. Based on further studies, 
he was diagnosed with primary hypothyroidism and 
growth hormone deficiency. Initially the pituitary mass 
was thought to be a macroadenoma and was considered 
for surgery is efficacious because of its location and size. 
On further evaluation, it was more likely that the mass 
might be caused by his long-standing untreated 
hypothyroidism. After six months of treatment with 
levothyroxine, he became clinically euthyroid and growth 
arrest was resolved. Follow up MRI showed the size of 
sellar mass was definitely decreased.
Sellar and suprasellar masses can be caused by several 
factors. However, it is clinically not easy to discriminate 
from many causes of sellar mass in children. There were 
several reasons we could not easily distinguish secondary 
pituitary hyperplasia from pituitary adenoma in this case. 
First, there is no specific diagnostic tool. MRI and CT 
have proven to have a low specificity in diagnosing 
pituitary hyperplasia and distinguishing it from pituitary 
adenomas[6]. Second, baseline concentration of alpha 
subunit was elevated. And thyrotropin-releasing hormone 
(TRH) stimulation test showed typically blunted response. 
Table 1. The results of serial endocrinological tests
Reference value Before treatment After treatment
T3 (nmol/L) 1.23~3.08 0.62   2.86 
freeT4 (pmol/L)  9.4~25.1 0.64  15.96
TSH (mIU/L) 0.3~4.0 > 100   0.6
Testosterone (nmol/L)  8.5~63.7 2.81   5.95
GH (μg/L)  0~9.5 < 0.01   0.11
Prolactin (μg/L)   0~15.0 21.02   6.42
LH (IU/L) 0.1~8.9 1.70   2.97
FSH (IU/L) 0.2~8.4 8.84   3.38
Cortisol (nmol/L) 193.1~689.8 298.28  97.45
ACTH (pmol/L)  2.2~13.2 10.29  11.12
IGF-1 (nmol/L) 26.46~126.46 12.66  46.78
Free alpha-subunit (mIU/mL)  0~0.8 > 8.0   0.3
Anti-thyroglobulin Ab (U/mL)   0~60.0 99.6  65.6
Anti-TPO Ab (U/mL)   0~60.0 > 3,000 910.5
TSH, thyroid stimulating hormone; GH, growth hormone; LH, luteinizing hormone; FSH, follicular stimulating hormone; ACTH, 
adrenocorticotropic hormone; IGF-1, insulin-like growth factor-1; Ab, antibody; TPO, thyroid peroxidase.
Table 2. The results of combined pituitary function test
Time (min) 0 15 30 60 90 120
Glucose (mmol/L)   4.83  2.28   2.61   2.39   3.39   3.77
GH (μg/L) < 0.01   0.90   0.76   0.57   0.38
Cortisol (nmol/L) 298.28 519.99 611.95 482.44 465.33
ACTH (pmol/L)  10.29  15.64   7.81  11.11   9.24
Prolactin (μg/L)  21.02 52.32  47.02  37.92  27.59
TSH (mIU/L) > 100 > 100 > 100 > 100 > 100 > 100
FSH (IU/L)   8.84 10.79  12.50  13.42  13.77
LH (IU/L)   1.70  2.70   2.14   3.25   3.42
GH, growth hormone; ACTH, adrenocorticotropic hormone; TSH, thyroid stimulating hormone; FSH, follicular stimulating 
hormone; LH, luteinizing hormone.
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National Institutes of Health study reported that baseline 
concentration of alpha subunit in the case series of 25 
patients with TSH secreting tumors was generally elevated 
(range: 0.9~135 μg/L). Serum alpha subunit in patients 
with pituitary hyperplasia never reached the level observed 
in subjects having primary pituitary tumors[7]. Another 
series showed that only four of nine patients with 
TSH-producing tumors had normal TSH responses to the 
TRH stimulation test[8]. Third, the mass size was larger 
than any other previous reports. Earlier reports indicated 
that physiological hypertrophy of the pituitary gland may 
be one of the differential diagnoses in this kind of patient. 
One study reported that relatively large mean height of the 
pituitary gland (8.2 mm) in an adolescent female patient 
on CT scans represented pubertal hypertrophy[9]. Furthermore 
Elster et al. reported definite evidence of physiological 
hypertrophy of the pituitary gland could be detected by 
MRI and the average height of the pituitary gland of a 
teenage boy was 8~10 mm[10]. In our patient, the height 
was 18.1 mm, which is much larger than the average 
height when there is physiological hypertrophy of the 
pituitary gland and also larger than any other secondary 
pituitary hyperplasia previously reported[11].
Despite these reasons, we preferred pituitary hyperplasia 
rather than pituitary tumor. First, this patient had already 
diagnosed with hypothyroidism. Second, he had no specific 
neurological presentation. Third, alpha subunit/TSH ratio of 
the present patient was less than 1. In fact, the clinical 
diagnosis of hypothyroidism is often delayed and the 
increased availability of MRI may lead to more cases 
presenting with pituitary findings. Interpretation of the 
brain imaging as a primary pituitary tumor without any 
evidence of endocrinological laboratory parameters can 
lead to unnecessary surgery with potential catastrophic 
results[5]. Therefore, serum TSH and prolactin levels 
should be appropriately measured in all patients found to 
have a pituitary mass. 
Unlike adults, children rarely have neurological 
presentations secondary to sellar expansion[12]. In 
prepubescent children, at the age ranging 8 to 14, pituitary 
hyperplasia was present in both boys as well as girls. 
Most children presented with signs of growth arrest. TSH 
levels were elevated with low free T4 concentrations along 
with enlargement of the sella turcica. From review of the 
literature, it appears that similar high doses of thyroid 
hormone replacement therapy were required for treatment. 
However, longer periods of treatment were needed for 
pituitary regression. Fortunately, congenital hypothyroidism 
and pituitary hyperplasia are rarely found in children in 
developed countries due to increased neonatal screening. 
It is also interesting that this patient had 
hyperprolactinemia. Hyperprolactinemia is a common 
feature in patients with hypothyroidism[13]. The 
hyperprolactinemia seems to be of limited clinical 
significance in adults[14] and often, but not always, 
resolves with thyroid hormone replacement[15]. The 
pathophysiology of the increased serum prolactin level is 
not clear, however it may be attributed to a mass effect, 
the ‘stalk effect’[16], or elevated TRH levels[17]. Pure 
prolactinomas can also present with mass effects and MRI 
findings rather than endocrine manifestations. These 
pituitary adenomas tend to respond well to medical 
treatment and can usually be diagnosed on the basis of 
biochemical results. Cases of superfluous surgical 
interventions without full endocrinological evaluation have 
been previously described[4,5,19].
Another important finding is that, on admission, the 
level of IGF-1 and GH were decreased. However, 2 month 
after levothyroxine and growth hormone replacement, 
IGF-1 level was normalized. Furthermore, his height 
increased as the level of 50th centile. Even though we did 
not check up the level of GH again, another report 
demonstrated that the level of GH was normalized after 
thyroid hormone replacement. It might suggest that GH 
deficiency was caused by hypothyroidism and it was just 
temporary[18]. For further evaluation, we plan to perform 
combined pituitary function test again after discontinue 
GH.
Summary
Our patient had many findings similar to those 
previously reported. However, the concentration of alpha 
subunit, alpha subunit/TSH ratio was much higher than 
normal range and mass size was very huge comparing to 
other patients. As a consequence, physician who first met 
him could not easily differentiate pituitary hyperplasia 
from pituitary tumor. 
The pituitary hyperplasia associated with hypothyroidism 
responds well to thyroid hormone replacement therapy. 
Normalization of the serum TSH with thyroxine 
replacement in hypothyroidism associated pituitary 
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hyperplasia predicts regression of the mass, excluding the 
presence of autonomous TSH secretion. Confirmation of 
resolution of the mass should be sought by monitoring 
visual fields and performing MRI after treatment. Thus, 
careful history taking, and reexamination of thyroid 
function in patients with sellar and suprasellar masses 
revealed by MRI may prevent unnecessary operations. 
요   약
소아에서 일차성 갑상선기능저하증으로 인한 뇌하수체증
식증은 매우 드물게 나타나는 것으로 알려져 있다. 그리고 
하시모토 갑상선염에 의한 갑상선기능저하증과 성장장애가 
동반된 상태로 뇌하수체종양과 유사한 뇌하수체증식증이 발
생하는 경우는 많지 않다. 본 증례는 하시모토 갑상선염에 
의한 일차성 갑상선기능저하증에 의해 성장장애와 뇌하수체
증식증을 보인 경우이다. 환자는 혈액검사에서 갑상선자극
호르몬의 수치가 증가되어 있고 갑상선호르몬의 수치가 감
소된 일차성 갑상선기능저하증의 양상을 보였으며 성장호르
몬 수치가 감소되어 있고 발육 및 성선발달이 저하되어 있
었다. 뇌자기공명영상에서 뇌하수체종양과 다른 양상의 뇌
하수체증식증이 의심되는 소견을 보였다. 환자는 갑상선기
능저하증에 의해 뇌하수체가 이차적으로 과증식한 상태로 
판단되어 갑상선호르몬 보충요법 및 성장호르몬 치료를 시
행하였고 치료 시작 3개월 후 시행한 뇌자기공명영상 및 혈
액검사에서 정상 뇌하수체 크기 및 정상 갑상선호르몬, 갑상
선자극호르몬 수치를 보였다. 또한 신장 발달 역시 정상화 
되었다. 따라서 갑상선기능저하증이 있으면서 영상검사에서 
뇌하수체종양이 의심되는 경우에는 불필요한 수술적 치료로 
인한 수술 합병증을 막기 위해서 반드시 철저한 병력 청취 
및 내분비 기능검사를 통해 갑상선기능저하증으로 인한 이
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